<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over a period of 8 years 11 of 64 patients seen at Loyola University Medical Center with the diagnosis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) also exhibited <z:hpo ids='HP_0005528'>bone marrow hypoplasia</z:hpo> (marrow cellularity of 25% or less) at presentation </plain></SENT>
<SENT sid="1" pm="."><plain>The other 53 had normocellular or hypercellular marrow </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical features, hemograms, chromosome analysis, incidence of progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and survival in each group were compared </plain></SENT>
<SENT sid="3" pm="."><plain>Using the French-American-British (FAB) classification, there were seven patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), one <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), and three <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in the hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group </plain></SENT>
<SENT sid="4" pm="."><plain>Those with normocellular or hypercellular marrow included 22 with RA, nine with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 12 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, three with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and four with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation; one had <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">diGuglielmo syndrome</z:e> and two patients were not classified </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> had lower <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels (median, 8 g/dl versus 9 g/dl), more severe <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> (median 3100/microliter versus 4200/microliter) and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (median, 28,000/microliter versus 75,000/microliter), and marked <z:mp ids='MP_0000248'>macrocytosis</z:mp> (mean corpuscular volume (MCV), 107 mu 3 versus 97 mu 3) </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients with hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> had a chromosome analysis of the bone marrow, and <z:hpo ids='HP_0000001'>all</z:hpo> were <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>In those with normocellular or hyperplastic bone marrow, 22 such analyses were done, and seven (23%) were abnormal </plain></SENT>
<SENT sid="8" pm="."><plain>One patient (11%) from the hypoplastic group and 11 (23%) from the normocellular or hyperplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed into <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>None progressed to <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>With a mean follow-up time of 33 months in the hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, eight patients (72%) are alive </plain></SENT>
<SENT sid="11" pm="."><plain>In the group with <z:mpath ids='MPATH_458'>normal</z:mpath> or hyperplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the mean follow up was 47 months, and 27 patients (50%) have survived </plain></SENT>
<SENT sid="12" pm="."><plain>The two groups differ significantly in leukocyte count (P less than 0.0015), platelet count (P less than 0.0001), and MCV (P less than 0.0023) </plain></SENT>
<SENT sid="13" pm="."><plain>There may be a possible difference between these groups related to abnormal karyotype, but it is not statistically significant (P = 0.06) </plain></SENT>
<SENT sid="14" pm="."><plain>Therapy with <z:chebi fb="5" ids="16709">pyridoxine</z:chebi>, <z:chebi fb="9" ids="27470">folic acid</z:chebi>, <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:e sem="disease" ids="C1456831" disease_type="Mental or Behavioral Dysfunction" abbrv="">anabolic steroids</z:e>, <z:chebi fb="0" ids="26537">retinoids</z:chebi>, or low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> was not beneficial in hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Hypoplastic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> appears to be a distinct clinicopathologic entity characterized by marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath>, <z:mp ids='MP_0000248'>macrocytosis</z:mp>, severe <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, low incidence of progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, and unresponsiveness to conventional therapy </plain></SENT>
</text></document>